In a T-ALL mouse xenograft study, unedited CD7 CAR T-cells supplemented with the tyrosine kinase inhibitors ibrutinib and dasatinib led to robust ex vivo expansion with minimal fratricide, as well as reduced terminal differentiation [70]. This evidence concerns the gene CD7 and acute lymphoblastic leukemia.